ArticleJournal of mid-life health
Evaluation of Different Diagnostic Modalities for Screening and Molecular Characterization of Human Papillomavirus Causing Cervical Cancer.
Article in Journal of mid-life health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer remains a major global health challenge, ranking as the fourth most common cancer and a leading cause of cancer-related deaths among women. Persistent infection with human papillomavirus (HPV) is recognized as the primary etiological factor. Effective screening methods such as HPV DNA testing, Papanicolaou (Pap) smear cytology, and visual inspection with acetic acid (VIA) are critical for early detection, particularly in resource-limited settings. Aim: This study evaluated the performance of different diagnostic approaches for cervical cancer screening and assessed the prevalence and distribution of HPV genotypes among symptomatic women in northern India, with special emphasis on high-risk genotypes beyond HPV16 and 18. Materials and Methods: A cross-sectional observational study was conducted over 21 months, which enrolled 200 symptomatic females attending a tertiary care center. Cervical specimens were analyzed using real-time polymerase chain reaction for HPV, including 14 high-risk genotypes. VIA and Pap smear tests were concurrently performed. Associations between variables and HPV status were analyzed using Pearson's Chi-square and Fisher's exact tests. Results: High-risk genotypes were detected in 22 participants (11%). HPV16 was the predominant genotype (6%), followed by HPV39 (3.5%). Other oncogenic types, including HPV45, 51, 56, 58, and 66, were also detected. Significant associations were found between HPV positivity and VIA results ( Conclusion: HPV DNA testing demonstrated superior diagnostic accuracy, confirming its role as the gold standard for cervical cancer screening. VIA and Pap smear remain cost-effective alternatives in low-resource settings. The detection of high-risk genotypes beyond HPV16 and 18 emphasizes the need for broader-spectrum HPV vaccines and tailored screening strategies to reduce cervical cancer burden in northern India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.